Prognostically meaningful tricuspid regurgitation (TR) is not well‐defined in the mitral transcatheter edge‐to‐edge repair arena. We aimed to explore the prevalence, correlates, and consequences of TR ...

Diagnosis and management can be challenging due to potential underestimation of mitral regurgitation severity from Impella and acute clinical deterioration upon removal. We present a case of ...

Degenerative mitral valve disease is common. Up to a quarter of patients with degenerative mitral valve disease may be asymptomatic despite having severe valve regurgitation. Current guideline ...

Transcatheter Repair Versus Surgery for Atrial Versus Ventricular Functional Mitral Regurgitation – A Post-Hoc Analysis of the MATTERHORN Trial. Circulation 2024;Oct 30:[Epub ahead of print].

Less commonly, rupture of a papillary muscle may arise as an iatrogenic complication of cardiac procedures. We present a case of cardiogenic shock in the setting of torrential mitral regurgitation ...

While there are multiple approaches to addressing degenerative mitral valve disease, cardiac surgeons tend to prefer repair over replacement, says James Gammie, co-director of the Johns Hopkins Heart ...

Echo parameters: The beneficial effect of transcatheter mitral valve replacement compared with GDMT alone was consistent in all echocardiographic subgroups, independent of the severity of LV ...

Mitral valve repair (MVRepair) has become the procedure of choice to correct severe degenerative mitral regurgitation (MR), due to its documented superiority to valve replacement regarding long-term ...

Yes! I want to get the latest chemistry news from C&EN in my inbox every week. ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly ...

Trace and access cover is a feature of your buildings insurance policy. It covers the cost of finding the source of a leak and making sure tradespeople can access it for repairs. Usually you'll find ...

Trace Neuroscience launched on Tuesday to announce that it is developing a genetic treatment targeting UNC13A, a gene linked to both a higher risk of ALS and faster disease progression.